Court Approves Vermillion's Plan of Reorganization; Company Raises $43M | GenomeWeb

Vermillion's Chapter 11 reorganization plan was approved by US Bankruptcy Court in Delaware on Thursday, the company announced.

As a result, the company will launch head-first into efforts to commercialize its OVA1 tumor triage diagnostic for ovarian cancer with Quest Diagnostics. The test received 510(k) clearance from the US Food and Drug Administration in September and the court's approval of Vermillion's reorganization plan had been expected.

Vermillion filed for Chapter 11 protection in late March.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.